ABSTRACT
The aim of our study is to assess the value of 99mTc-hexakis-2-methoxyisobutylisonitrile [MIBI] scintigraphy to detect viable boney tumor in patients with clinical and radiological features of primary or metastatic skeletal tumors. This is a prospective study included thirty six patients with different bone malignancies [17 cases with primary lesions and 19 cases with metastatic boney lesions]. All patients were subjected to Tc99m MDP bone scan [BS] and Tc99m MIBI scans. Planar whole body scintigraphy was performed 2 hours after intravenous injection of 20-30 mCi of Tc99m MDP, and after 1 to 2 weeks a Tc-99m MIBI scan was performed using 15-20 mCi and planar imaging was done 15 min post injection. Thirty of 36 patients represented by bone lesions in BS showed increased MIBI uptake, with sensitivity 83.3%. In cases of primary bone tumors 3 patients out of 17 showed no tracer uptake in MIBI scan and also 3 patients of metastatic bone lesions out of 19 showed no tracer uptake in MIBI scan. The MIBI scan can detect more 41 sites of tracer uptake in these patients not seen in Bs. Tc-99m MDP bone and Tc-99m MIBI scans are complementary to each other. The sensitivity of detection of malignant bone tumor is more for combined BS and MIBI than each one alone